Skip to main content
RemeGen Co., Ltd. logo

RemeGen Co., Ltd. — Investor Relations & Filings

Ticker · 9995 ISIN · CNE1000048G6 LEI · 300300M9HCX4TFAD4I10 HKEX Manufacturing
Open in API
Filings indexed 1,625 across all filing types
Latest filing 2022-04-19 Report Publication Anno…
Country CN China
Listing HKEX 9995

About RemeGen Co., Ltd.

http://www.remegen.com

RemeGen Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on creating first-in-class and best-in-class therapeutics to address significant unmet clinical needs, particularly in the critical therapeutic areas of autoimmune diseases, oncology, and ophthalmology. RemeGen utilizes proprietary technology platforms capable of discovering, screening, and developing new molecules and efficiently optimizing production processes. Its pipeline includes a series of innovative biologics, such as Telitacicept, and features 8 clinical pipelines, over 40 clinical trials, and more than 600 patent applications, demonstrating a strong commitment to R&D and innovation in biopharmaceuticals.

Recent filings

Filing Released Lang Actions
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2022-04-19 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Report Publication Announcement Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2022-04-19 English
ARTICLES OF ASSOCIATION
Governance Information Classification · 95% confidence The document is titled 'Articles of Association of RemeGen Co., Ltd.' and contains detailed chapters on company governance, share issuance, board structure, senior management, financial and accounting systems, merger and capital changes, and dispute resolutions. It references relevant laws and regulations governing company operations and shareholder rights. The content is a comprehensive legal and governance framework document for the company rather than a financial report, earnings release, or announcement. It does not contain financial statements or results, nor is it a brief announcement or presentation. Therefore, it fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2022-04-19 English
ANNOUNCEMENT ON INCREASE OF REGISTERED CAPITAL OF THE COMPANY AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION
Capital/Financing Update Classification · 95% confidence The document is an announcement by RemeGen Co., Ltd. regarding an increase in registered capital and amendments to the Articles of Association following the completion of an A Share Offering. It references regulatory approvals, share issuance, and changes to the company's capital structure. The document is an announcement of corporate actions related to capital increase and amendments to governance documents, not a full financial report or detailed presentation. It does not contain financial statements or detailed financial analysis but rather informs shareholders and the market about changes in share capital and related articles. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2022-04-19 English
Notification Letter and Request Form to Non-Registered Holders - Notice of Publication of Extraordinary General Meeting Notice and Proxy Form ("Current Corporate Communications")
Report Publication Announcement Classification · 95% confidence The document is a notification letter dated 20 April 2022 from RemeGen Co., Ltd. addressed to non-registered shareholders. It informs recipients about the publication of the Extraordinary General Meeting (EGM) Notice and Proxy Form, and provides instructions on how to access these corporate communications electronically or request printed versions. The document includes a request form for shareholders to specify their preferred language and format for receiving corporate communications. There is no substantive financial data, analysis, or detailed report content present. Instead, it is an announcement about the availability and distribution of corporate communications related to an EGM. The document length is 6826 characters, which is relatively short and consistent with a notification letter rather than a full report. Therefore, according to the "Menu vs Meal" rule, this document is best classified as a Report Publication Announcement (RPA), as it announces the publication of the EGM notice and proxy form rather than containing the full report itself.
2022-04-19 English
PROXY FORM FOR USE AT THE 2022 FIRST EXTRAORDINARY GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a proxy form for the 2022 first extraordinary general meeting of RemeGen Co., Ltd. It includes instructions for appointing a proxy to vote on resolutions, specifically the appointment of an independent non-executive director. The content is procedural and related to shareholder voting rather than financial results, management reports, or regulatory filings. It is not a report or announcement of financial performance or governance changes but a form used to facilitate voting at a shareholder meeting. This fits the category of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2022-04-19 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.